tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

SNDX Stock Latest News

Syndax, WODA collaborate to launch program to expand access to Revuforj
The FlySyndax, WODA collaborate to launch program to expand access to Revuforj
5d ago
SNDX
Syndax Pharmaceuticals Modernizes Bylaws for Electronic Share Issuance
PremiumCompany Announcements
Syndax Pharmaceuticals Modernizes Bylaws for Electronic Share Issuance
23d ago
8K
SNDX
Promising Growth Prospects for Syndax Pharmaceuticals: Buy Rating Affirmed by Analyst
PremiumRatings
Promising Growth Prospects for Syndax Pharmaceuticals: Buy Rating Affirmed by Analyst
1M ago
SNDX
Promising Potential of Syndax Pharmaceuticals’ Revuforj in AML Treatment Drives Buy Rating
PremiumRatings
Promising Potential of Syndax Pharmaceuticals’ Revuforj in AML Treatment Drives Buy Rating
1M ago
SNDX
Syndax price target raised to $35 from $22 at Barclays
PremiumThe Fly
Syndax price target raised to $35 from $22 at Barclays
2M ago
SNDX
Syndax price target lowered to $33 from $40 at JPMorgan
PremiumThe FlySyndax price target lowered to $33 from $40 at JPMorgan
2M ago
SNDX
Syndax Pharmaceuticals: Q3 Earnings Call Highlights
Premium
Company Announcements
Syndax Pharmaceuticals: Q3 Earnings Call Highlights
2M ago
SNDX
Syndax price target raised to $38 from $35 at UBS
Premium
The Fly
Syndax price target raised to $38 from $35 at UBS
2M ago
SNDX
Strong Growth Potential and Market Expansion Justify Buy Rating for Syndax Pharmaceuticals
PremiumRatings
Strong Growth Potential and Market Expansion Justify Buy Rating for Syndax Pharmaceuticals
2M ago
SNDX
Syndax Pharmaceuticals: Strategic Advancements and Growth Potential Reinforce Buy Rating
PremiumRatings
Syndax Pharmaceuticals: Strategic Advancements and Growth Potential Reinforce Buy Rating
2M ago
SNDX
Syndax price target raised to $22 from $19 at Barclays
PremiumThe Fly
Syndax price target raised to $22 from $19 at Barclays
2M ago
SNDX
Syndax Pharmaceuticals Reports Strong Q3 2025 Growth
PremiumCompany Announcements
Syndax Pharmaceuticals Reports Strong Q3 2025 Growth
2M ago
SNDX
Syndax reports Q3 EPS (70c), consensus (71c)
PremiumThe FlySyndax reports Q3 EPS (70c), consensus (71c)
2M ago
SNDX
Syndax sees operating expense base remaining stable over next few years
Premium
The Fly
Syndax sees operating expense base remaining stable over next few years
2M ago
SNDX
Syndax options imply 10.9% move in share price post-earnings
Premium
The Fly
Syndax options imply 10.9% move in share price post-earnings
2M ago
SNDX
Syndax announces Revuforj, Niktimvo data accepted for presentation at ASH 2025
PremiumThe Fly
Syndax announces Revuforj, Niktimvo data accepted for presentation at ASH 2025
2M ago
SNDX
SNDX Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
SNDX Upcoming Earnings Report: What to Expect?
2M ago
SNDX
Syndax Pharmaceuticals Launches Promising Phase 3 AML Study with Revumenib
PremiumCompany Announcements
Syndax Pharmaceuticals Launches Promising Phase 3 AML Study with Revumenib
3M ago
SNDX
Syndax Pharmaceuticals’ Revumenib Study: A Potential Game-Changer in Leukemia Treatment
PremiumCompany Announcements
Syndax Pharmaceuticals’ Revumenib Study: A Potential Game-Changer in Leukemia Treatment
3M ago
SNDX
Syndax Pharmaceuticals’ Axatilimab Study: A Potential Breakthrough for IPF Treatment
PremiumCompany AnnouncementsSyndax Pharmaceuticals’ Axatilimab Study: A Potential Breakthrough for IPF Treatment
3M ago
SNDX
Syndax Pharmaceuticals’ Promising AML Study Update: Key Insights for Investors
Premium
Company Announcements
Syndax Pharmaceuticals’ Promising AML Study Update: Key Insights for Investors
3M ago
SNDX
Syndax price target raised to $27 from $26 at BofA
Premium
The Fly
Syndax price target raised to $27 from $26 at BofA
3M ago
SNDX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >